AstraZeneca’s Truqap (capivasertib) became the first AKT inhibitor approved in the EU for breast cancer patients with one or more PIK3CA/AKT1/PTEN-alterations. Dave Fredrickson, executive vice president of the company’s oncology business unit, noted Thursday that the authorisation “represents a significant step forward in providing an important new treatment option for patients in need of new, innovative therapies.”
Clearance from the European Commission was based on results from the Phase III CAPItello-291 trial in which the combination of Truqap and Faslodex reduced the risk of disease progression or death by 50% versus Faslodex in combination with placebo in patients with tumours harbouring PI3K/AKT/PTEN-alterations. A regulatory application based on the data is also under review in China.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.